"studyRationale","id","studyVersion","studyAcronym","uuid:ID","studyTitle"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2","H2Q-MC-LZZT","925ea7a3-06d9-44e5-af0a-c16c70c0cf3e","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease"
